/
We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
The business is unprofitable at the operating level (-39.79% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 4.1%, steady but not accelerating.
Negative free cash flow of -$13M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$37M
▲ +4.1% YoY
Net Income (TTM)
-$12M
▲ +60.4% YoY
Op. Margin
-37.38%
▲ +6.4pp YoY
ROIC
-31.10%
▲ +0.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▲ +14.8% YoY
Op. Cash Flow (TTM)
-$10M
▲ +14.2% YoY
Net Debt
$24M
Cash & Equiv.
$5M
3Y CAGR: +2.2%
Continue Research